ZALTRAP

(Zaltrap)

PreclinicalBiologic

AAzienda U.S.L. 1 di Massa e Carrara

ZALTRAP is one of 52 biologic programs targeting Colorectal Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[2]

Indication

Colorectal CarcinomaUnknown

Colorectal CarcinomaPreclinical

Unknown

Competition

Competitive Landscape

102 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

2 2

Iressa

AstraZeneca

Phase 3

1 3

Sutent

Pfizer

Phase 3

1 4

Avastin

BBio-Thera Solutions

Phase 3

5 5

Vectibix

Golytely

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

2 9

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

1 10

Camptosar

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Regulatory

FDA Approval Timeline[3]

Aug 3, 2012

ZALTRAP

BLA BLA125418

Sources

References

[1]
ChEMBL — Zaltrap compound record. European Bioinformatics Institute (EMBL-EBI).
[2]
Open Targets Platform — Drug–disease associations for Zaltrap. EMBL-EBI & Wellcome Sanger Institute.
[3]
OpenFDA — FDA approval records (BLA BLA125418). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Azienda U.S.L. 1 di Massa e Carrara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[1]
Highest Phase: Preclinical
Company: AAzienda U.S.L. 1 di Massa e Carrara

ZALTRAP

Status by Indication[2]

Competitive Landscape

FDA Approval Timeline[3]

References

Drug Info

Quick Facts

Related News